Vanda Pharmaceuticals Inc.: Business Overview, Financials & Competitive Analysis
Vanda Pharmaceuticals Inc. scores 7/10 on the AskCyborg Cyborg Score (Strong). Rare disease specialist with transformative recent approvals positioned for significant revenue growth through multiple commercial launches in 2026. Vanda demonstrates strong momentum with two recent FDA approvals, robust pipeline with near-term regulatory catalysts, and extended patent protection through 2044. However, the company faces operational and legal challenges that temper.
What is Vanda Pharmaceuticals Inc.'s industry? Vanda Pharmaceuticals Inc. (vandapharma.com) operates in Biopharmaceutical - Specialty Pharma (CNS/Psychiatry and Rare Diseases). AskCyborg classifies Vanda Pharmaceuticals Inc. under Biopharmaceutical - Specialty Pharma (CNS/Psychiatry and Rare Diseases) in its company registry.
Vanda is a leading global biopharmaceutical company focused on the development and commercialization of innovative therapies to address high unmet medical needs and improve the lives of patients. The company is a clin...
Cyborg Score thesis
Rare disease specialist with transformative recent approvals positioned for significant revenue growth through multiple...
Read the full analyst-debate transcript →Get the Latest Vanda Pharmaceuticals Inc. Report
Up-to-date AI-powered research, analyst debate audio & saved-company playlists
Get Current Report FreeVanda Pharmaceuticals Inc. Overview
Pro stress-test →Vanda is a leading global biopharmaceutical company focused on the development and commercialization of innovative therapies to address high unmet medical needs and improve the lives of patients. The company is a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for central nervous system (CNS) disorders and rare diseases, with research and development efforts centered on sleep-wake regulation, mood disorders, and movement disorders.
Strategic Profile
Pro stress-test →The company has achieved two significant FDA approvals including BYSANTI™ (milsaperidone) tablets for acute treatment of manic or mixed episodes associated with bipolar I disorder and schizophrenia, and NEREUS™ in December 2025. With Bysanti on track for a 2026 launch, Vanda is positioned to capture market share in treating bipolar disorder and schizophrenia with patent and data exclusivity protection until 2044. The company has advanced regulatory review with FDA acceptance of imsidolimab BLA for treating Generalized Pustular Psoriasis, with a target action date of December 12, 2026.
Competitive Landscape
Pro stress-test →Vanda competes in psychiatric and rare disease markets against established players like Johnson & Johnson (Janssen), Eli Lilly, and Lundbeck in antipsychotics, while rare disease opportunities face limited direct competition due to small patient populations. The company differentiates through precision medicine approaches utilizing genetic characterization and extended patent exclusivity.
Industry Context
Vanda Pharmaceuticals Inc. operates in Biopharmaceutical - Specialty Pharma (CNS/Psychiatry and Rare Diseases).
Key facts
Founded: 2003 · Headquarters: Washington, DC